{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:45:43Z","timestamp":1745311543127},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s10741-005-7301-6","type":"journal-article","created":{"date-parts":[[2005,5,11]],"date-time":"2005-05-11T08:29:08Z","timestamp":1115800148000},"page":"337-345","source":"Crossref","is-referenced-by-count":9,"title":["Neurohormonal Intervention to Reduce Sudden Cardiac Death in Heart Failure: What is the Optimal Pharmacologic Strategy?"],"prefix":"10.1007","volume":"9","author":[{"given":"Iain","family":"Squire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR1","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0735-1097(97)00361-6","volume":"30","author":"BF Uretsky","year":"1997","unstructured":"Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking? J Am Coll Cardiol 1997;30:1589\u20131597.","journal-title":"J Am Coll Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0002-8703(97)70173-X","volume":"133","author":"BM Massie","year":"1997","unstructured":"Massie BM, Shah NB. Evolving trends in the epidemiologic factors in heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703\u2013712.","journal-title":"Am Heart J"},{"issue":"Suppl 1","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR3","first-page":"19","volume":"85","author":"MD Meissner","year":"1992","unstructured":"Meissner MD, Akhtar M, Lehmann MH. Nonischemic sudden tachycardia in atherosclerotic death in atherosclerotic heart disease. Circulation 1992;85(Suppl 1):19\u201324.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0002-9149(88)91295-7","volume":"61","author":"FI Marcus","year":"1988","unstructured":"Marcus FI, Cobb LA, Edwards JE, et al. Mechanism of death and prevalence of myocardial ischaemic symptoms in the terminal event after acute myocardial infarction. Am J Cardiol 1988;61:8\u201315.","journal-title":"Am J Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR5","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/01.CIR.80.6.1675","volume":"80","author":"M Luu","year":"1989","unstructured":"Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675\u20131680.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/01.CIR.102.6.611","volume":"102","author":"BF Uretsky","year":"2000","unstructured":"Uretsky BF, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death. Circulation 2000;102:611\u2013616.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR7","unstructured":"\u00d8rn S, Cleland JGF, Romo M, Kjekshus J, Dickstein K. Recurrent infarction is the most common cause of death in patients with left ventricular dysfunction following myocardial infarction. Am. J. Med (in Press)."},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1253\/jcj.61.727","volume":"61","author":"WG Stevenson","year":"1997","unstructured":"Stevenson WG, Sweeney MO. Arrhythmias and sudden death in heart failure. Jpn Circ J 1997;61:727\u2013740.","journal-title":"Jpn Circ J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1023\/A:1020001912248","volume":"7","author":"BN Singh","year":"2002","unstructured":"Singh BN. Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. Heart Failure Rev 2002;7:285\u2013300.","journal-title":"Heart Failure Rev"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.CIR.93.3.519","volume":"93","author":"CM Pratt","year":"1996","unstructured":"Pratt CM, Greenway PS, Schoenfeld MH, et al. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation 1996;93:519\u2013524.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1161\/01.CIR.65.3.457","volume":"65","author":"LE Hinkle Jr.","year":"1982","unstructured":"Hinkle LE Jr, Thaler HT. Clinical classification of cardiac deaths. Circulation 1982;65:457\u2013464.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1161\/01.CIR.69.2.250","volume":"69","author":"JT Bigger Jr.","year":"1984","unstructured":"Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250\u2013258.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0002-9149(83)80141-6","volume":"51","author":"JA Franciosa","year":"1983","unstructured":"Franciosa JA, Wilen M, Ziesche S, et al. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983;51:831\u2013836.","journal-title":"Am J Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/heart.89.1.42","volume":"89","author":"PA Poole-Wilson","year":"2003","unstructured":"Poole-Wilson PA, Uretsky BF, Thygesen K, et al. Mode of death in heart failure: Findings from the ATLAS trial. Heart 2003;89:42\u201348.","journal-title":"Heart"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR15","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/01.CIR.94.12.3198","volume":"94","author":"HC Doval","year":"1996","unstructured":"Doval HC, Nul DR, Grancelli HD, et al. Nonsustained ventricular tachycardia in heart failure: Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation 1996;94:3198\u20133203.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/01.CIR.0000047275.25795.17","volume":"107","author":"MT La Rovere","year":"2003","unstructured":"La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003;107:565\u2013570.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689\u20131697.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR18","first-page":"H1609","volume":"277","author":"H Kawai","year":"1999","unstructured":"Kawai H, Fan TH, Dong E, et al. ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure. Am J Physiol 1999;277:H1609\u20131617.","journal-title":"Am J Physiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR19","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","volume":"144","author":"AD Struthers","year":"2002","unstructured":"Struthers AD, Aldosterone: Cardiovascular assault. Am Heart J 2002;144:S2\u20137.","journal-title":"Am Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR20","first-page":"310","volume":"2","author":"SG Williams","year":"2000","unstructured":"Williams SG, Tan LB. Aldosterone antagonists: Current and future perspectives. Curr Opin Cardiovasc Pulmon Renal Invest Drugs 2000;2:310\u2013315.","journal-title":"Curr Opin Cardiovasc Pulmon Renal Invest Drugs"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/0002-8703(83)90003-0","volume":"106","author":"AL Wit","year":"1983","unstructured":"Wit AL, Rosen MR. Pathophysiologic mechanisms of cardiac arrhythmias. Am Heart J 1983;106:798\u2013811.","journal-title":"Am Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","volume":"37","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001;37:1047\u20131052.","journal-title":"Hypertension"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1742-1241.2003.tb10466.x","volume":"57","author":"LR Erhardt","year":"2003","unstructured":"Erhardt LR. Endothelial dysfunction and cardiovascular disease: The promise of blocking the renin-angiotensin system. Int J Clin Pract 2003;57:211\u2013218.","journal-title":"Int J Clin Pract"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0002-9149(98)00862-5","volume":"83","author":"KK Koh","year":"1999","unstructured":"Koh KK, Bui MN, Hathaway L, et al. Mechanism by which quinapril improves vascular function in coronary artery disease. Am J Cardiol 1999;83:327\u2013331.","journal-title":"Am J Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/01.HYP.35.1.501","volume":"35","author":"L Ghiadoni","year":"2000","unstructured":"Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000;35:501\u2013506.","journal-title":"Hypertension"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1460-9592.2003.00036.x","volume":"26","author":"F Gensini","year":"2003","unstructured":"Gensini F, Padeletti L, Fatini C, et al. Angiotensin-converting enzyme and endothelial nitric oxide synthesis polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 2003;26:295\u2013298.","journal-title":"Pacing Clin Electrophysiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0008-6363(02)00243-2","volume":"54","author":"Y Shi","year":"2002","unstructured":"Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456\u2013461.","journal-title":"Cardiovasc Res"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR28","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/01.CIR.100.4.376","volume":"100","author":"OD Pedersen","year":"1999","unstructured":"Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376\u2013380.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00045391-199909000-00005","volume":"6","author":"V Ranade","year":"1999","unstructured":"Ranade V, Molnar J, Khokher T, et al. Effect of angiotensin-converting enzyme therapy on QT interval dispersion. Am J Ther 1999;6:257\u2013261.","journal-title":"Am J Ther"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0140-6736(94)91164-9","volume":"343","author":"CS Barr","year":"1994","unstructured":"Barr CS, Naas A, Freeman M, et al. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327\u2013329.","journal-title":"Lancet"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0895-7061(98)00036-3","volume":"11","author":"AJ Manolis","year":"1998","unstructured":"Manolis AJ, Beldekos D, Handanis S, et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: Effects on LVH regression and arrthythmogenic propensity. Am J Hypertens 1998;11:640\u2013648.","journal-title":"Am J Hypertens"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000006956","volume":"92","author":"L Wang","year":"1999","unstructured":"Wang L. ACE inhibitors suppress ischemia-induce arrhythmia by reducing the spatial dispersion of ventricular repolarization. Cardiology 1999;92:106\u2013109.","journal-title":"Cardiology"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR33","first-page":"189","volume":"46","author":"PK Hasija","year":"1998","unstructured":"Hasija PK, Karloopia SD, Shahi BN, et al., Exercise-induced ventricular arrhythmias in congestive heart failure and role of ACE inhibitors. J Assoc Physicians India 1998;46:189\u2013193.","journal-title":"J Assoc Physicians India"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR34","doi-asserted-by":"crossref","unstructured":"The SOLVD Investigators, Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293\u2013302.","DOI":"10.1056\/NEJM199108013250501"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR35","doi-asserted-by":"crossref","unstructured":"The CONSENSUS Trial Study Group, Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429\u20131435.","DOI":"10.1056\/NEJM198706043162301"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303\u2013310.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-8703(96)90559-1","volume":"132","author":"C Torp-Pedersen","year":"1996","unstructured":"Torp-Pedersen C, Kober L, Carlsen J. On behalf of the Trace Study Group, Angiotensin-converting enzyme inhibition after myocardial infarction: The Trandolapril Cardiac Evaluation study. Am Heart J 1996;132:235\u2013243.","journal-title":"Am Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/18.1.41","volume":"18","author":"JGF Cleland","year":"1997","unstructured":"Cleland JGF, Erhardt L, Murray G, et al. On behalf of the AIRE Study Investigators, Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. Eur Heart J 1997;18:41\u201351.","journal-title":"Eur Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM199501123320203","volume":"332","author":"E Ambrosioni","year":"1995","unstructured":"Ambrosioni E, Borghi C, Magnani B. For The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators, The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80\u201385.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669\u2013677.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR41","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","volume":"360","author":"K Dickstein","year":"2002","unstructured":"Dickstein K, Kjekshus J and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group, Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Lancet 2002;360:752\u2013760.","journal-title":"Lancet"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR42","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","volume":"349","author":"MA Pfeffer","year":"2003","unstructured":"Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893\u20131906.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR43","first-page":"I5","volume":"67","author":"E Lichstein","year":"1983","unstructured":"Lichstein E, Morganroth J, Harrist R, et al. Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience. Circulation 1983;67:I5\u201310.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR44","first-page":"I53","volume":"67","author":"S Goldstein","year":"1983","unstructured":"Goldstein S. For the BHAT Research Group, Propranolol therapy in patients with acute myocardial infarction: The Beta-Blocker Heart Attack Trial. Circulation 1983;67(Suppl 1):I53\u2013156.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR45","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.CIR.82.3.941","volume":"82","author":"KC Dellsperger","year":"1990","unstructured":"Dellsperger KC, Martins JB, Clothier JL, et al. Incidence of sudden cardiac death associated with coronary artery occlusion in dogs with hypertension and left ventricular hypertrophy is reduced by chronic \u03b2 -adrenergic blockade. Circulation 1990;82:941\u2013950.","journal-title":"Circulation"},{"issue":"9B","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR46","doi-asserted-by":"crossref","first-page":"23J","DOI":"10.1016\/S0002-9149(97)00835-7","volume":"80","author":"PC Deedwania","year":"1997","unstructured":"Deedwania PC, Carbajal EV, Role of beta blockade in the treatment of myocardial ischemia. Am J Cardiol 1997;80(9B):23J\u201328J.","journal-title":"Am J Cardiol"},{"issue":"Suppl 6","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR47","first-page":"V184","volume":"84","author":"K Egstrup","year":"1991","unstructured":"Egstrup K. Silect ischemia and beta-blockade. Circulation 1991;84(Suppl 6):V184\u2013192.","journal-title":"Circulation"},{"issue":"Suppl 1","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR48","first-page":"293","volume":"85","author":"W Haverkamp","year":"1990","unstructured":"Haverkamp W, Gulker H, Hindricks G, et al. Effects of beta-blockade on the incidence of ventricular tachyarrhythmias during acute myocardial ischemia: Experimental findings and clinical implications. Basic Res Cardiol 1990;85(Suppl 1):293\u2013303.","journal-title":"Basic Res Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000441-199404000-00003","volume":"307","author":"J Patel","year":"1994","unstructured":"Patel J, Lee W, Fusilli L, et al. Anti-arrhythmic efficacy of beta-adrenergic blockade during ischemia in myocardium with scar. Am J Med Sci 1994;307:259\u2013263.","journal-title":"Am J Med Sci"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR50","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, et al. for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349\u20131355.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR51","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","volume":"90","author":"CIBIS Investigators and Committees","year":"1994","unstructured":"CIBIS Investigators and Committees. A randomized trial of \u03b2 -blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765\u20131773.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS Investigators and Committees","year":"1999","unstructured":"CIBIS Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9\u201313.","journal-title":"Lancet"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR53","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","volume":"283","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, et al. for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295\u20131302.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR54","doi-asserted-by":"crossref","first-page":"I98","DOI":"10.1007\/s003950070017","volume":"95","author":"A Hjalmarson","year":"2000","unstructured":"Hjalmarson A, Fagerberg B on behalf of the MERIT-HF Study Group. MERIT-HF mortality and morbidity data. Basic Res Cardiol 2000;95(Suppl 1):I98\u2013103.","journal-title":"Basic Res Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR55","doi-asserted-by":"crossref","unstructured":"The BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659\u20131667.","DOI":"10.1056\/NEJM200105313442202"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR56","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1054\/S1071-9164(03)00133-7","volume":"9","author":"MJ Domanski","year":"2003","unstructured":"Domanski MJ, Krause-Steinrauf H, Massie BM, et al. for the BEST Investigators. A comparative analysis of the results from 4 trials of \u03b2 -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Cardiac Failure 2003;9:354\u2013362.","journal-title":"J Cardiac Failure"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR57","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194\u20132199.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR58","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0735-1097(01)01516-9","volume":"38","author":"S Goldstein","year":"2001","unstructured":"Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol controlled release\/extended release in patients with heart failure: Analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001;38:932\u2013938.","journal-title":"J Am Coll Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR59","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0002-8703(03)00163-7","volume":"146","author":"A J\u00e1nosi","year":"2003","unstructured":"J\u00e1nosi A, Ghali JK, Herliz J, et al. On behalf of the MERIT-HF Study Group, Metoprolol CR\/XL in postmyocardial infarction patients with chronic heart failure: Experiences from MERIT-HF. Am Heart J 2003;146:721\u2013728.","journal-title":"Am Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"The CAPRICORN Investigators","year":"2001","unstructured":"The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001;357:1385\u20131390.","journal-title":"Lancet"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR61","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/hrt.82.1.57","volume":"82","author":"RJ MacFadyen","year":"1999","unstructured":"MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57\u201361.","journal-title":"Heart"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR62","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","volume":"19","author":"P Vantrimpont","year":"1998","unstructured":"Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998;19:1552\u20131563.","journal-title":"Eur Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR63","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","volume":"345","author":"KT Weber","year":"2001","unstructured":"Weber KT, Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689\u20131697.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0002-9149(94)90362-X","volume":"74","author":"H Tsuji","year":"1994","unstructured":"Tsuji H, Venditti FJ Jr, Evans JC, et al. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994;74:232\u2013235.","journal-title":"Am J Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR65","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0735-1097(10)80329-8","volume":"16","author":"SS Gottlieb","year":"1990","unstructured":"Gottlieb SS, Baruch L, Kukin ML, et al. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol 1990;16:827\u2013831.","journal-title":"J Am Coll Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR66","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CA Farquharson","year":"2000","unstructured":"Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594\u2013597.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR67","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/cs1030425","volume":"103","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002;103:425\u2013431.","journal-title":"Clin Sci"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0735-1097(01)01729-6","volume":"39","author":"J Bauersachs","year":"2002","unstructured":"Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351\u2013358.","journal-title":"J Am Coll Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR69","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1161\/hc4601.099485","volume":"104","author":"T Heitzer","year":"2001","unstructured":"Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673\u20132678.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR70","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967\u20132972.","journal-title":"Circulation"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","volume":"141","author":"MG Modena","year":"2001","unstructured":"Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41\u201346.","journal-title":"Am Heart J"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR72","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","volume":"24","author":"W Wang","year":"1994","unstructured":"Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994;24;571\u2013575.","journal-title":"Hypertension"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/cs0950687","volume":"95","author":"KM Yee","year":"1998","unstructured":"Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci 1998;95:687\u2013692.","journal-title":"Clin Sci"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR74","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","volume":"76","author":"CS Barr","year":"1995","unstructured":"Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259\u20131265.","journal-title":"Am J Cardiol"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR75","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0008-6363(97)00091-6","volume":"35","author":"RJ MacFadyen","year":"1997","unstructured":"MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30\u201334.","journal-title":"Cardiovasc Res"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709\u2013717.","journal-title":"N Engl J Med"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR77","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309\u20131321.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR78","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1071-9164(03)00474-3","volume":"9","author":"B Pitt","year":"2003","unstructured":"Pitt B, Zannad F, Bittman R, et al. The EPHESUS Trial: Evaluation of eplerenone in the subgroup of patients with baseline left ventricular ejection fraction \u226430%. Journal of Cardiac Failure 2003;9(Suppl 1):S57.","journal-title":"Journal of Cardiac Failure"},{"key":"techbooks_nopdfdoi_2005-05-09_09-40-40_CR79","unstructured":"Advisory Council to Improve Outcomes Nationwide in Heart Failure, Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83:1A\u201338A."}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-005-7301-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-005-7301-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-005-7301-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T06:02:12Z","timestamp":1683093732000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-005-7301-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["7301"],"URL":"https:\/\/doi.org\/10.1007\/s10741-005-7301-6","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}